Companies › Changchun Intellicrown Pharmaceutical
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology, Gastroenterology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IMM-H014 | – | Phase 1 | Nonalcoholic Steatohepatitis (NASH) | – |
| ZZ06 EGFR-targeting biologic (mechanism unclear) | – | Phase 1 | Advanced EGFR Positive Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06216041 | IMM-H014 | Phase 1 | Nonalcoholic Steatohepatitis (NASH) | Gastroenterology | Jun 2025 |
| NCT04412616 | ZZ06 | Phase 1 | Advanced EGFR Positive Solid Tumor | Oncology | Dec 2025 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.